East Africa: Regional Countries Move to Monitor Drugs Released Into Market

Photo: Pixabay
Thermometer and pills.

Rwanda, Tanzania, Ethiopia and Kenya have launched a programme to monitor drugs released into the market.

Under a project, dubbed "Pharmacovigilance Infrastructure and Post-Marketing Surveillance System Capacity building for Regional Medicine Regulatory Harmonisation," participating countries will train pharmacists and other medical personnel on safety, particularly the collection, analysis, monitoring and prevention of adverse effects of drugs and therapies.

A consortium that has been formed will build partnerships between local academic institutions and national medicine regulatory authorities as it seeks to strengthen the region's drug safety and post-marketing surveillance system for medicines.

Among the drugs the project is expected to monitor are the HPV vaccine rollout in Ethiopia and a mass drug administration campaign targeting lymphatic filariasis or elephantiasis in the Coastal counties of Kenya.

According to Prof Ellen Aklillu of the Karolinska Institutet -- one of the partner in the project -- little is known about the safety levels of drugs released for large-scale use on the continent after clinical trials targeting a small population.

Additionally, the drugs were often given to target populations in mass drug administration and vaccination campaigns without pre-screening.

"Drugs are given, and no follow-up is done on each individual. We need to find out what happens for instance if a patient is taking drugs for TB and he or she has other conditions," said Prof Aklillu.

Related Content

New treatments offer hope for tropical diseases in Africa

She added that areas to be monitored will include how the drug interacts with pregnant women, breastfeeding mothers, children and the elderly.

She said variation in people's genetic make-up was very wide, and that drugs were not likely to react with all of them the same way, necessitating the need for comprehensive and wide monitoring of the their use.


In June, the US Food and Drugs Administration and the European Medicines Agency warned against the use of antiretroviral medication Dolutegravir, also known as Tivicay, by pregnant HIV-positive women.

In response to the warning, the Kenyan government directed county governments not to give the drug to pregnant women with HIV in the first trimester or those hoping to conceive.

Director of Medical Services Jackson Kioko also instructed county health directors to give Efavirenz, a first-line treatment, to women of childbearing age.

He said DTG, also known as Tivicay, was not recommended for pregnant and breastfeeding women "due to limited safety data."

The World Health Organisation guidelines released in 2016 recommend Efavirenz, also known as Sustiva, as the preferred option in pregnancy.

The project is funded by the European-Developing Countries Clinical Trials Platform, which is a funding mechanism under the EU's Horizon 2020 research programme.

Other partners include the Swedish Karolinska Institutet, the Dutch Stichting Lareb, and the University of Nairobi.

See What Everyone is Watching

More From: East African

Don't Miss

AllAfrica publishes around 600 reports a day from more than 150 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.